Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial

Lau, David C.W.; Erichsen, Lars; Francisco, Ann Marie Ocampo; Satylganova, Altynai; Roux, Carel W. le; McGowan, Barbara; Pedersen, Sue D.; Pietiläinen, Kirsi H.; Rubino, Domenica; Batterham, Rachel L.

doi:10.1016/s0140-6736(21)01751-7

Cited by 120 publications

(76 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Currently, therapeutic drugs and lifestyle interventions are recommended for obese and diabetic patients to alleviate metabolic problems such as obesity and diabetic. However, no matter the lifestyle intervention, medication or RYGB surgery, there are many problems such as poor efficacy, poor drug compliance, and other adverse reactions 148–150 . Many previous animal and human studies have demonstrated the important role of intestinal flora in host energy metabolism.…”

Section: Clinical Application Of Gut Microbiotamentioning

confidence: 99%

“…However, no matter the lifestyle intervention, medication or RYGB surgery, there are many problems such as poor efficacy, poor drug compliance, and other adverse reactions. [148][149][150] Many previous animal and human studies have demonstrated the important role of intestinal flora in host energy metabolism. In addition to directly affecting various physiological functions of the host in the intestinal tract, the gut microbiota also indirectly affects the host circulation through metabolites.…”

Section: Clinical Application Of Gut Microbiotamentioning

confidence: 99%

See 1 more Smart Citation

Gut and obesity/metabolic disease: Focus on microbiota metabolites

Lin

Zhu

2022

MedComm

View full text Add to dashboard Cite

Obesity is often associated with the risk of chronic inflammation and other metabolic diseases, such as diabetes, cardiovascular disease, and cancer. The composition and activity of the gut microbiota play an important role in this process, affecting a range of physiological processes, such as nutrient absorption and energy metabolism. The active gut microbiota can produce a large number of physiologically active substances during the process of intestinal metabolism and reproduction, including short‐chain/long‐chain fatty acids, secondary bile acids, and tryptophan metabolites with beneficial effects on metabolism, as well as negative metabolites, including trimethylamine N‐oxide, delta‐valerobetaine, and imidazole propionate. How gut microbiota specifically affect and participate in metabolic and immune activities, especially the metabolites directly produced by gut microbiota, has attracted extensive attention. So far, some animal and human studies have shown that gut microbiota metabolites are correlated with host obesity, energy metabolism, and inflammation. Some pathways and mechanisms are slowly being discovered. Here, we will focus on the important metabolites of gut microbiota (beneficial and negative), and review their roles and mechanisms in obesity and related metabolic diseases, hoping to provide a new perspective for the treatment and remission of obesity and other metabolic diseases from the perspective of metabolites.

show abstract

Section: Clinical Application Of Gut Microbiotamentioning

confidence: 99%

Section: Clinical Application Of Gut Microbiotamentioning

confidence: 99%

Gut and obesity/metabolic disease: Focus on microbiota metabolites

Lin

Zhu

2022

MedComm

View full text Add to dashboard Cite

show abstract

“…Moreover, with the highest cagrilintide dose, 88.7%, 53.5% and 18.7% of people achieved weight loss of at least 5%, 10% and 15%, respectively. Gastrointestinal (GI) disorders and administration‐site reactions were the most frequent adverse events, occurring in 41%–63% of the cagrilintide groups, compared with 60% of the liraglutide group and 32% of people taking placebo 98 …”

Section: Treatment Of Obese People With T2dmentioning

confidence: 99%

“…Gastrointestinal (GI) disorders and administration‐site reactions were the most frequent adverse events, occurring in 41%–63% of the cagrilintide groups, compared with 60% of the liraglutide group and 32% of people taking placebo. 98 …”

Section: Treatment Of Obese People With T2dmentioning

confidence: 99%

Managing weight and glycaemic targets in people with type 2 diabetes—How far have we come?

Blüher

Ceriello

Davies

et al. 2022

Endocrino Diabet & Metabol

View full text Add to dashboard Cite

Introduction:As the vast majority of people with type 2 diabetes (T2D) are also overweight or obese, healthcare professionals (HCP) are faced with the task of addressing both weight management and glucose control. In this narrative review, we aim to identify the challenges of reaching and maintaining body weight targets in people with T2D and highlight current and future treatment interventions.Methods: A search of the PubMed database was conducted using the search terms "diabetes" and "weight loss."Results: According to emerging evidence, treating obesity may be antecedent to the development and progression of T2D. While clinical benefits typically set in upon achieving a weight loss of 3-5%, these benefits are progressive leading to further health improvements, and weight loss of >15% can have a disease-modifying effect in people with T2D, an outcome that up to recently could not be achieved with any blood glucose-lowering pharmacotherapy. However, advanced treatment options with weight-loss effects currently in development including the dual GIP/GLP-1 receptor agonists may enable simultaneous achievement of individual glycemic and weight goals. Conclusion:Despite considerable therapeutic progress, there is still a large unmet medical need in patients with T2D who miss their individualized glycemic and weightloss targets. Nonetheless, it is to be expected that development of future therapies and their use will favourably change the scenario of weight and glucose control in T2D.

show abstract

“…183-190) discuss in their contribution the role of amylin, a natural pancreatic hormone that induces satiety, in the management of obesity and results from recent preclinical and clinical studies. One potential future strategy of the medical management of obesity could use the novel approach of a combination therapy of a long-acting amylin analogue with an established gastrointestinal incretin GLP-1 analogue [19,20].…”

mentioning

confidence: 99%

Gastrointestinal regulatory peptides

Weber

2022

Current Opinion in Endocrinology, Diabetes &Amp; Obesity

View full text Add to dashboard Cite

Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial

Cited by 120 publications

References 47 publications

Gut and obesity/metabolic disease: Focus on microbiota metabolites

Gut and obesity/metabolic disease: Focus on microbiota metabolites

Managing weight and glycaemic targets in people with type 2 diabetes—How far have we come?

Gastrointestinal regulatory peptides

Contact Info

Product

Resources

About